ReviewAmerican journal of translational research2026
Impact of SGLT-2 inhibitors on long-term prognosis in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
Review in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to assess the effect of Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitor (SGLT-2i) on long-term (≥1 year) mortality, heart failure (HF)-related hospital admissions, and safety in patients suffering from heart failure with preserved ejection fraction (HFpEF), via a systematic review and meta-analysis of recent high-quality randomized controlled trials (RCTs), and further provide the updated evidence to inform clinical management strategies.
methodsA systematic literature search was conducted in PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov. Pooled risk ratios (RR) with 95% confidence intervals (CI) were calculated using either a random-effects or fixed-effect model, selected based on heterogeneity as measured by Q test and the I
resultsA total of six international multicenter RCTs published between 2020 and 2025, enrolling 16,543 participants, were included in the meta-analysis. The findings showed that treatment with SGLT-2i significantly reduced the risk of heart failure hospitalizations when compared to placebo (P<0.05). A significant reduction in all-cause mortality was also observed in the SGLT-2 inhibitor group. Rates of adverse events were similar between the SGLT-2 inhibitor and placebo arms. Besides, funnel plot analysis showed no significant publication bias.
conclusionIn patients with HFpEF, SGLT-2 inhibitor therapy safely reduces the risk of heart failure hospitalization and mortality. These findings support the use of SGLT-2 inhibitors as a valuable treatment strategy in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.